<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="17091" end="17094" sStart="17045" offset="46" sid="r8.way.n.0435" wn="2" wnkey="way%1:04:01::" text="Currently, ovarian biopsy is the only way to diagnose autoimmune premature ovarian failure with certainty." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="4231" end="4237" sStart="null" offset="239" sid="r11.strong.j.0127" wn="1" wnkey="strong%3:00:00::" text="Binding of antibody to the zona pellucida at a 1:10 dilution was reported by the laboratory on a scale of 0 to 3+ according to the intensity of fluorescence: 0, negative; 1+, weak; 2+ moderate or 3+ strong fluorescence (Figure 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="12710" end="12716" sStart="null" offset="31" sid="r11.severe.j.0398" wn="1" wnkey="severe%5:00:00:intense:00" text="This approach can have severe adverse consequences such as the development of osteonecrosis related to glucocorticoid therapy [ 4 ] . Here we demonstrate that detection of ovarian antibodies by indirect immunofluorescence using one specific commercial test system has poor specificity as a diagnostic test." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1472-6874-3-2.anc" start="9162" end="9166" sStart="null" offset="0" sid="null" wn="4" wnkey="read%2:31:06::" text="We therefore redefined the outcome measure to be &lt;b&gt;read&lt;/b&gt; simply as positive (+) or negative (-)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1472-6874-3-2.anc" start="18465" end="18469" sStart="null" offset="0" sid="null" wn="1" wnkey="read%2:31:00::" text="All authors &lt;b&gt;read&lt;/b&gt; and approved the final manuscript." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="8921" end="8925" sStart="null" offset="35" sid="r7.poor.j.0357" wn="4" wnkey="poor%3:00:02::" text="Because the 1+ and 2+ readings had poor reproducibility, we were concerned that this inaccuracy might have impaired our ability to detect a difference between patients and control women." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="12987" end="12991" sStart="null" offset="308" sid="r7.poor.j.0218" wn="5" wnkey="poor%5:00:00:insufficient:00" text="This approach can have severe adverse consequences such as the development of osteonecrosis related to glucocorticoid therapy [ 4 ] . Here we demonstrate that detection of ovarian antibodies by indirect immunofluorescence using one specific commercial test system has poor specificity as a diagnostic test." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="8921" end="8925" sStart="null" offset="35" sid="r7.poor.j.0357" wn="4" wnkey="poor%3:00:02::" text="Because the 1+ and 2+ readings had poor reproducibility, we were concerned that this inaccuracy might have impaired our ability to detect a difference between patients and control women." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="10706" end="10712" sStart="null" offset="13" sid="r9.normal.j.0631" wn="3" wnkey="normal%3:00:03::" text="Eleven of 26 normal women (42%) had ovarian antibodies whereas none of the 26 normal men had these antibodies ( P &lt; 0.001)." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="10791" end="10797" sStart="null" offset="98" sid="r9.normal.j.0475" wn="3" wnkey="normal%3:00:03::" text="Eleven of 26 normal women (42%) had ovarian antibodies whereas none of the 26 normal men had these antibodies ( P &lt; 0.001)." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="13409" end="13415" sStart="null" offset="190" sid="r9.normal.j.0131" wn="3" wnkey="normal%3:00:03::" text="We found that women with premature ovarian failure are significantly more likely to have positive thyroid peroxidase and parietal cell autoantibodies than women with normal ovarian function." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="1727" end="1731" sStart="null" offset="61" sid="r10.high.j.0818" wn="1" wnkey="high%3:00:02::" text="We found that this commercially available test has a high incidence of false positives." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="5615" end="5619" sStart="null" offset="26" sid="r11.dark.j.0457" wn="1" wnkey="dark%3:00:01::" text="The slides were kept in a dark moist chamber until evaluated using a Zeiss Axiophot Fluorescent Microscope (Carl Zeiss Inc., Thornwood, NY) at 40? magnification with emission at 400 nM and excitation at 520-560 nM." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="9487" end="9494" sStart="null" offset="75" sid="r10.control.n.0335" wn="4" wnkey="control%1:09:02::" text="Tests were then repeated using serum from the 26 patients and 26 control women." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="2467" end="2472" sStart="null" offset="92" sid="r10.board.n.0799" wn="1" wnkey="board%1:14:00::" text="The National Institute of Child Health and Human Development Institutional Review Board approved the protocol." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="17731" end="17738" sStart="null" offset="128" sid="r11.benefit.n.0186" wn="2" wnkey="benefit%1:07:00::" text="Hence, this ovarian antibody test as presently performed has poor specificity, and therefore appears to have no benefit in the evaluation and management of autoimmune premature ovarian failure." />
    <s path="[OANC]/data/written_2/technical/biomed/1472-6874-3-2.anc" start="17712" end="17719" sStart="null" offset="109" sid="r9.appear.v.0641" wn="1" wnkey="appear%2:39:00::" text="Hence, this ovarian antibody test as presently performed has poor specificity, and therefore appears to have no benefit in the evaluation and management of autoimmune premature ovarian failure." />
  </sentences>
</list>